overview of laboratory of bacterial polysaccharides l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Overview of Laboratory of Bacterial Polysaccharides PowerPoint Presentation
Download Presentation
Overview of Laboratory of Bacterial Polysaccharides

Loading in 2 Seconds...

play fullscreen
1 / 21

Overview of Laboratory of Bacterial Polysaccharides - PowerPoint PPT Presentation


  • 183 Views
  • Uploaded on

Overview of Laboratory of Bacterial Polysaccharides. By Willie F. Vann, Chief LBP. Description of the Laboratory of Bacterial Polysaccharides.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Overview of Laboratory of Bacterial Polysaccharides' - bernad


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
description of the laboratory of bacterial polysaccharides
Description of the Laboratory of Bacterial Polysaccharides
  • The Laboratory of Bacterial Polysaccharides investigates the biochemistry, biology, chemistry, and immunology of virulence factors of encapsulated bacteria.
  • These virulence factors include capsular polysaccharides, lipopolysaccharides, and outer membrane proteins.
description of the laboratory of bacterial polysaccharides continued
Description of the Laboratory of Bacterial Polysaccharides (continued)
  • The Laboratory of Bacterial Polysaccharides has review responsibility for submissions related to polysaccharide and polysaccharide conjugate vaccines in addition to non-capsular immunogens of encapsulated pathogens.
chronology of laboratory of bacterial polysaccharides
Chronology of Laboratory of Bacterial Polysaccharides
  • 2002
    • Last Site Visit
  • 2004
    • CE Frasch steps down as Lab Chief
    • MS Blake becomes Acting Lab Chief
  • 2006
    • WF Vann appointed Lab Chief
    • Glycobiology Group of Lab of Bacterial Toxins joined Lab of Bacterial Polysaccharides
    • NMR and Mass Spectrometry groups of Lab of Biophysics joined Lab of Bacterial Polysaccharides
areas of research
Areas of Research
  • Structure and conformation of capsular polysaccharides
  • Biosynthesis of capsular polysaccharides
  • Role of non-capsular antigens in protection
  • Interaction of the capsular polysaccharides with the immune system
  • Development of methodology for analysis of conjugate vaccines
relevance of research program to cber mission
Relevance of Research Program to CBER Mission
  • The Laboratory of Bacterial Polysaccharides has regulatory responsibility for vaccines against encapsulated bacteria and products containing bacterial polysaccharides
  • The overall goal of the research program of the LBP is to understand the virulence factors that are components of vaccines against bacterial pathogens.
relevance of research program to cber mission continued
Relevance of Research Program to CBER Mission (continued)
  • The research program of the Laboratory of Bacterial Polysaccharides is directed toward understanding the physical, chemical, and immunological properties of bacterial polysaccharides, and polysaccharide conjugate vaccines
  • The knowledge and expertise gained in this research endeavor provide a scientific basis for our decisions related to the review of manufacturing, purity, potency, and safety of carbohydrate containing vaccines.
some significant achievements
Some Significant Achievements
  • Development of Efficient Method for Meningococcal Group A Conjugate Vaccine Synthesis
    • Vaccine in MVP/WHO Sponsored Phase II Clinical Trial
meningococcal group a conjugate vaccine project managed by ce frasch cber m laforce mvp
Meningococcal Group A Conjugate Vaccine Projectmanaged by CE Frasch - CBER & M. LaForce – MVP

Gates Foundation

Daron Freedberg and Scott Norris contributed to analysis during development

some significant achievements analytical biochemistry chaoming tsai pi
Some Significant AchievementsAnalytical Biochemistry – ChaoMing Tsai, PI
  • Developed HPAEC method for quantitation of phosphate and acetylation in polysaccharide vaccines
  • Characterized the lgtH gene of Neisseria LOS gene cluster
  • Demonstrated that the LOS of commensal N. polysaccharea is similar to LOS of meningococcal pathogen
some significant achievements molecular epidemiology margaret bash
Some Significant AchievementsMolecular Epidemiology – Margaret Bash
  • Developed and applied molecular methods to study PorB diversity
      • Horizontal genetic exchange (mosaicism) predominates
      • Persistence of PorB variable region sequence types indicates diversification is constrained
      • Identified survival advantages associated with PorB types
      • Relevant to development and evaluation of broadly protective OMP vaccines
some significant achievements cellular immunology mustafa akkoyunlu pi
Some Significant AchievementsCellular Immunology-Mustafa Akkoyunlu, PI
  • Interactions of bacterial capsular polysaccharides with innate immune system.
    • Neisseria meningitidis type C polysaccharide binding to CD14 and LBP inhibits meningococcal LPS mediated cell activation
  • Modulation of BAFF/APRIL system molecules by microbial products.
    • Decreased expression of TACI on newborn mouse B cells may to be responsible for the impaired response of newborns to polysaccharide antigens.
    • Toll-like receptor agonists, CpG DNA and LPS, strongly upregulate TACI expression on B cells.
some significant achievements structural biology daron freedberg pi
Some Significant AchievementsStructural Biology-Daron Freedberg, PI

1. On cell NMR: In-vivo antigen characterization by NMR

Mening B PS structure on cells = Mening B PS structure in vaccine

m=monomer

p=polymer

2. Carbohydrate 3D Structure: Sucrose

regulatory accomplishments
Regulatory Accomplishments
  • Licensing Tetravalent Meningococcal Conjugate Diphtheria Toxoid Vaccine – against groups A,C, Y, and W-135
    • Reviewers included Frasch, Tsai, Lee, Bash, Lynn, Blake
  • Significant Changes in Analytical Methodology for Lot Release
    • Reviewers included Tsai, Freedberg
other regulatory accomplishments
Other Regulatory Accomplishments
  • IND Supplement Reviewed – 350
  • BLA & BLA Supplement Review -85
  • Participated in International and CBER Policy Working Groups
  • Distributed Reference Material for Haemophilus and Pneumococcal Antibody Assays